This effect is most pronounced during early treatment and may diminish with continued therapy
Those savings aside, customers should not expect a meaningful slowing of the ever-rising cost of coverage, Blue Cross chief actuary Mike Guerriere said
A high level of GIP and GLP-1 binding causes increased insulin secretion, leading to stronger control over glucose in the body [6]
Jos Morales, MD, a vascular neurologist and neurointerventional surgeon at Providence Saint Johns Health Center in Santa Monica, CA, also not involved in this review, told MNT that microglias effect on the neurovascular unit has been associated with dementia. He suggested that: [GLP-1 drugs] could potentially modulate inflammation to reduce the propensity for developing dementias such as Alzheimers disease, particularly in the setting of metabolic syndrome. Morales also explained that in people who have glycemia or type 2 diabetes, the inflammation of the blood-brain barrier can lead to progressive damage to the brain over longer periods. He noted that trials that combine neuroimaging techniques that measure the blood-brain barrier and GLP-1 treatment are needed and could prove that these drugs have neuroprotective benefits.
Additionally, injecting into areas with potentially reduced absorption, or failing to rotate injection sites may result in inconsistent drug delivery